Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sosei Group ( (JP:4565) ) has provided an announcement.
Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, including Phase 2–ready lead candidate NXE0048149, after Boehringer Ingelheim chose not to exercise its exclusive licensing option. The decision triggers the return to Nxera of all data and intellectual property generated under the collaboration and leaves the company free to pursue new strategic options, including a formal out‑licensing process in 2026, without affecting its current-period consolidated financial results.
NXE0048149, designed using Nxera’s NxWave discovery platform, has shown a highly favorable safety profile in Phase 1 studies, dose-proportional pharmacokinetics and pharmacodynamic evidence of engaging brain circuitry relevant to schizophrenia, supporting once‑daily dosing and continued development. With GPR52 expression linked to positive, negative and cognitive symptom domains, Nxera believes the program could offer a first‑in‑class treatment that addresses shortcomings of existing therapies, and management views the return of full rights as a strategic opportunity to partner the asset with a major pharmaceutical or specialized neuroscience company.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen858.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing specialty medicines to address unmet medical needs in Japan and globally. Through its NxWave structure-based drug design platform, the company is advancing a pipeline of more than 30 programs spanning obesity and metabolic disorders, neurology and neuropsychiatry, and immunology and inflammation, while operating an agile commercial business in Japan and the broader Asia-Pacific region. Nxera, which employs around 400 staff across Japan, the UK, Switzerland and South Korea, markets several launched products and is listed on the Tokyo Stock Exchange (ticker: 4565).
Average Trading Volume: 745,506
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen77.83B
See more insights into 4565 stock on TipRanks’ Stock Analysis page.